Diabetes drug shown not to increase heart failure risk

Diabetes drug shown not to increase heart failure risk
A new study published in the medical journal The Lancet concludes that the diabetes drug Alogliptin does not carry significant increased risk for heart disease. Credit: Shutterstock

People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist just published in the British medical journal The Lancet.

Dr. William White, professor of medicine and chief of the Calhoun Cardiology Center Division of Hypertension and Clinical Pharmacology at UConn Health, analyzed data from a global clinical trial called EXAMINE. Regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new diabetic therapies.

"This new analysis shows that Alogliptin was safe in patients with Type 2 diabetes who we considered at high cardiovascular risk because they had had an before entering the trial," says White.

Even in patients who had a history of heart failure – 28 percent of participants – there was no increase in hospitalization.

The information is significant because of the prevalence of morbidity and mortality in patients with Type 2 diabetes. According to the World Health Organization, heart disease is responsible for between 50 percent and 80 percent of deaths among diabetics.

Also, the findings contradict a previous clinical trial of another diabetes medication in the same drug class that showed a modest increase in risk, leading to a closer scrutiny of Alogliptin – an orally administered anti-diabetic drug in the DPP-4 inhibitor class – in the medical community.

EXAMINE is an acronym for "Examination of Cardiovascular Outcomes: Alogliptin vs. Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome." The study included nearly 5,400 diabetics in 49 countries, all of whom were within 90 days of hospitalization for either a heart attack or chest pain related to . The trial was funded by Japanese pharmaceutical company Takeda, which makes Alogliptin.

Explore further

Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS

More information: "Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial." DOI: dx.doi.org/10.1016/S0140-6736(14)62225-X
Journal information: The Lancet

Citation: Diabetes drug shown not to increase heart failure risk (2015, March 13) retrieved 31 March 2020 from https://medicalxpress.com/news/2015-03-diabetes-drug-shown-heart-failure.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments